[HTML][HTML] Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 Variants
Among the anti-Spike monoclonal antibodies (mAbs), the S-309 derivative sotrovimab was
the most successful in having the longest temporal window of clinical use, showing a high …
the most successful in having the longest temporal window of clinical use, showing a high …
[HTML][HTML] Quality control in SARS-CoV-2 RBD-Fc vaccine production using LC–MS to confirm strain selection and detect contaminations from other strains
P Suwanchaikasem, K Rattanapisit, R Strasser… - Scientific Reports, 2024 - nature.com
Abstract Coronavirus disease of 2019 (COVID-19), caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), is an ongoing outbreak, disrupting human life …
syndrome coronavirus 2 (SARS-CoV-2), is an ongoing outbreak, disrupting human life …
[HTML][HTML] Unveiling Therapeutic Dynamics: An In-depth Comparative Analysis of Neutralizing Monoclonal Antibodies and Favipiravir in Alleviating COVID-19 …
T Siripongboonsitti, K Tawinprai… - Journal of Infection and …, 2024 - Elsevier
Abstract Background Neutralizing monoclonal antibodies (NMabs) are recognized for their
efficacy against non-severe COVID-19. However, spike protein mutations may confer …
efficacy against non-severe COVID-19. However, spike protein mutations may confer …
Comparative effectiveness of sotrovimab versus no treatment in non-hospitalised high-risk COVID-19 patients in north west London: a retrospective cohort study
M Drysdale, ER Galimov… - BMJ Open …, 2024 - bmjopenrespres.bmj.com
Background We assessed the effectiveness of sotrovimab vs no early COVID-19 treatment in
highest-risk COVID-19 patients during Omicron predominance. Methods Retrospective …
highest-risk COVID-19 patients during Omicron predominance. Methods Retrospective …